Arcturus Therapeutics Holdings Inc. ARCT · NASDAQ
$10.87 +13.94% (+$1.33)
Summary
29 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $191.5M against $22.9M.
What to watch
- Revenue fell by 31% a year over the last 3 years.
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 73% this fiscal year.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 48% a year over 5 years. Over the last 3 years it fell by 31% a year. For the next fiscal year analysts expect revenue to fall by 73%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $93.3M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 5
- Sell 4
Today's price within the analysts' price targets
The average target of $30.5 is 181% above today's price. 57% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration Revenue 82%
- Grant 18%
By region
- Foreign Countries 100%
Collaboration Revenue brings in 82% of revenue. Grant grew fastest, by 293% a year.
Segments in detail